Additionally, the salbutamol treatment of septic rats presented increased of the SGLT1 activity and significant reduction of BAL pro-inflammatory cytokines, bronchial inflammation, atelectasis, and airway damage, suggesting a potential benefit in ARDS secondary to sepsis. The gene discussed is SLC5A1; the disease is Sepsis.